ATM and B-cell chronic lymphocytic leukemia: In the present investigation, which includes 3631 patients with CLL, we aimed to investigate the clinical impact of somatic mutations and/or deletions of ATM, with particular consideration of IGHV gene SHM status and other gene mutations associated with CLL prognosis, focusing primarily on early-stage patients.